Vericiguat Side Effects and Medication Safety Complete Guide

　　1.Basic Drug Information

　　Vericiguat tablets(Vericiguat),brand name Verquvo,is a soluble guanylate cyclase(sGC)stimulator mainly used to treat patients with chronic heart failure(NYHA class II-IV)and reduced ejection fraction(HFrEF).The drug directly stimulates sGC to increase cyclic guanosine monophosphate(cGMP)production,improving vasodilation and ventricular function,reducing cardiovascular death and heart failure hospitalization risk.

　　2.Hypotension Risk and Management

　　Hypotension is the most common adverse reaction to Vericiguat,with an incidence rate of approximately 16.4%.As the drug promotes vasodilation to lower blood pressure,some patients may experience dizziness,vertigo,or even syncope.Patients with lower baseline blood pressure(systolic pressure below 100mmHg)are at higher risk.Dose reduction or discontinuation is recommended when obvious hypotension symptoms occur.Avoid sudden standing to prevent orthostatic hypotension.Regular blood pressure monitoring is advised,especially during early treatment.

　　3.Anemia and Blood Cell Reduction

　　Clinical trials observed decreased hemoglobin levels during Vericiguat treatment,with an incidence rate of approximately 10%.This is because the cGMP pathway may affect red blood cell production.Although most hemoglobin decreases are mild to moderate,regular complete blood count monitoring is still required.Severe anemia may require blood transfusion or dose adjustment.

　　4.Gastrointestinal Reactions

　　Common gastrointestinal adverse reactions include nausea,diarrhea,dyspepsia,vomiting,and gastroesophageal reflux.These symptoms are usually mild to moderate and mostly appear during early treatment.Taking with meals may reduce nausea.If symptoms persist or worsen,symptomatic medication or dose adjustment can be used.

　　5.Headache and Neurological Symptoms

　　Headache is one of the common adverse reactions to Vericiguat,usually mild to moderate.Other neurological symptoms include dizziness,vertigo,and fatigue.These symptoms may be related to blood pressure changes caused by vasodilation.Most patients can tolerate them,but severe cases require medical evaluation.

　　6.Heart Rate Changes

　　Some patients may experience increased heart rate or palpitations.This may be related to vasodilation and reflex tachycardia.Patients with pre-existing arrhythmias or cardiac conduction blocks need special attention.Seek medical attention promptly if obvious palpitations or abnormal heart rate occurs.

　　7.Renal Function Effects

　　Vericiguat use requires caution in patients with renal impairment.Patients with mild to moderate renal impairment usually do not need dose adjustment,but data for severe renal impairment patients is limited.Vericiguat may affect renal function,requiring regular monitoring of serum creatinine and glomerular filtration rate during treatment.

　　8.Hepatic Function Effects

　　Vericiguat has relatively minor effects on the liver,but liver function still needs regular monitoring during treatment.When significant transaminase elevation occurs,evaluate whether it is drug-related and decide whether to adjust the treatment plan.

　　9.Drug Interactions

　　Vericiguat has relatively few interactions with other commonly used cardiovascular drugs.However,caution is needed when combined with certain nitrate drugs as it may enhance vasodilation effects.Patients using other sGC stimulators(such as Riociguat)should not use Vericiguat concurrently.Combination with phosphodiesterase inhibitors(such as Sildenafil)carries a risk of worsening hypotension.

　　10.Special Population Considerations

　　Vericiguat is contraindicated in pregnant women as it may cause fetal harm.Nursing women using this medication should stop breastfeeding.Data for patients with severe hepatic impairment is limited,requiring careful risk-benefit evaluation.Patients with rare congenital galactose intolerance,lactase deficiency,or glucose-galactose malabsorption should not use this medication.

　　11.Adverse Reaction Monitoring and Follow-up

　　During Vericiguat use,the following indicators should be regularly monitored:blood pressure(especially during early treatment),complete blood count,liver and kidney function,and heart rate.Communicate with your doctor promptly if any discomfort symptoms occur.Good monitoring helps timely detection and management of adverse reactions to ensure medication safety.The recommended starting dose is 2.5mg once daily,with dose doubling approximately every 2 weeks to reach the target maintenance dose of 10mg daily that the patient can tolerate.It should be taken orally with food.